We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fondaparinux for the Treatment of Acute Heparin-Induced Thrombocytopenia: A Single-Center Experience.
- Authors
Grouzi, Elisavet; Kyriakou, Elias; Panagou, Ioannis; Spiliotopoulou, Ioanna
- Abstract
Heparin-induced thrombocytopenia (HIT) is a life-threatening immune response to heparin that is associated with a high risk of thromboembolic complications. The syndrome is caused by antibodies that are reactive against complexes of platelet factor 4/heparin (PF4/H). For patients with HIT, the discontinuation of heparin alone is not sufficient and the diagnosis necessitates the administration of an alternative anticoagulant. Fondaparinux is a synthetic pentasaccharide that binds to antithrombin and potentiates inhibition of factor Xa. Data have shown that fondaparinux is structurally too short to induce an antibody response and could be a useful agent to treat HIT. In our hospital, we retrospectively analyzed the use of fondaparinux in the treatment of 24 patients with acute HIT during unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) administration and compared the results to a similar population of 20 patients who were treated with lepirudin. The treated patients had a complete platelet count recovery, and none experienced a new thromboembolic complication or major bleeding. The development of limb gangrene (2 patients who received lepirudin and 1 who received fondaparinux) likely resulted from a delay in diagnosis and treatment initiation. Our data suggest that fondaparinux may be considered a safe and an effective alternative treatment in HIT complicated with or without thrombosis.
- Publication
Clinical & Applied Thrombosis/Hemostasis, 2010, Vol 16, Issue 6, p663
- ISSN
1076-0296
- Publication type
Article
- DOI
10.1177/1076029609347900